The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.
Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...
“EFFISAYIL™ 2 is the first and largest multinational randomized clinical trial to evaluate a treatment for the prevention of GPP flares,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, ...
Please provide your email address to receive an email when new articles are posted on . 53.3% of 750 mg IV imsidolimab-treated patients achieved the primary endpoint vs. 13.3% of placebo. Imsidolimab ...
US FDA accepts Vanda Pharmaceuticals’ BLA for imsidolimab to treat Generalized Pustular Psoriasis: Washington Friday, February 27, 2026, 17:00 Hrs [IST] Vanda Pharmaceuticals In ...
Scalp rosacea is an uncommon skin condition causing discoloration or redness and pus-filled bumps on the top of the head. It tends to affect males in an atypical pattern. Rosacea is a chronic skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results